CSL
CSL Limited is a global biotechnology company specializing in the development, manufacturing, and marketing of life-saving biotherapies, vaccines, and diagnostic products. Its core business revolves around plasma-derived therapies, which treat a range of serious medical conditions, and recombinant technologies. CSL holds a leading market position in several therapeutic areas, leveraging its extensive research and development capabilities and global manufacturing and distribution network to deliver innovative healthcare solutions.
Short position
CSL (ASX:CSL) has 1.01% of its shares on issue reported as short positions as of 5 Oct 2026, or about 4,858,977 shares. Over the past 30 days that figure has fallen 0.43 percentage points, and over 90 days it has fallen 0.27 percentage points. Its highest recorded short interest was 3.33% in June 2010. CSL is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4CSL (CSL) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in USD, the reporting currency
- Revenue
- 15.70Bvs 15.43B (FY25)
- Yahoo Finance, as at 29 Sep 2026
- NPAT
- −2.58Bvs 3.00B (FY25)
- Yahoo Finance, as at 29 Sep 2026
- EPS (diluted)
- −5.35vs 6.17 (FY25)
- Yahoo Finance, as at 29 Sep 2026
- Rev YoY
- +1.7%FY
- EPS YoY
- n/mTTM
Key ratios
Year to 30 Jun 2026 (FY); balance sheet at 30 Jun 2026; prices to 9 Oct 2026
- Gross margin
- 50.8%
- Operating margin
- 19.8%
- Net margin
- −16.4%
- FCF margin
- 14.2%
- ROE
- −15.1%
- ROA
- −7.1%
- FCF conversion
- n/a
- Net debt (excl. leases)
- USD 7.87B
- Net debt / EBITDA
- 1.5×
- Current ratio
- 2.2×
- Interest cover
- 8.1×
- Cash dividends paid / net profit
- n/a
- Market cap
- $88.04B
- P/E
- n/a (reports in USD)
- P/B
- n/a (reports in USD)
Ratios use the reporting currency (USD); market cap is in AUD. Source: Yahoo Finance, as at 29 Sep 2026.
Financial statements
Figures in USD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | 15.70B | 15.43B | 14.69B | 13.17B |
| Gross profit | 7.98B | 7.95B | 7.56B | 6.71B |
| Operating income | 3.10B | 2.96B | 2.76B | 2.10B |
| EBITDA | −2.66B | 5.13B | 4.73B | 3.90B |
| EBIT | −3.71B | 4.12B | 3.79B | 3.07B |
| Interest expense | 382.0M | 393.0M | 420.0M | 408.0M |
| Pretax income | −4.09B | 3.72B | 3.38B | 2.66B |
| Tax | −1.10B | 588.0M | 661.0M | 419.0M |
| NPAT | −2.58B | 3.00B | 2.64B | 2.19B |
| Net interest income | −405.0M | −410.0M | −437.0M | −406.0M |
| EPS basic | −5.35 | 6.20 | 5.47 | 4.55 |
| EPS diluted | −5.35 | 6.17 | 5.45 | 4.53 |
| Shares | 478.9M | 484.2M | 483.3M | 482.4M |
Financial reports
The company's own filings, newest first
- CSL Half Year Results Investor PresentationHalf Year Results11 Feb 2026via asx_announcements
- CSL Half Year Results AnnouncementHalf Year Results11 Feb 2026via asx_announcements
- CSL Statutory Accounts for the Half Year Ended 31 DecemberHalf Year Results11 Feb 2026via asx_announcements
- CSL Half Year Results Investor PresentationHalf Year Results11 Feb 2025via asx_announcements
- CSL Half Year Results AnnouncementHalf Year Results11 Feb 2025via asx_announcements
- CSL Statutory Accounts for the Half Year Ended 31 Dec 2024Half Year Results11 Feb 2025via asx_announcements
- Notice of Investor/Analyst Briefing 2025 Half Year ResultHalf Year Results7 Feb 2025via asx_announcements
- Full Year Statutory Accounts for 30 June 2024Full Year Results13 Aug 2024via asx_announcements
- Half Year Results Investor PresentationHalf Year Results13 Feb 2024via asx_announcements
- Half Year Results AnnouncementHalf Year Results13 Feb 2024via asx_announcements
Showing 10 of 12 reports